Technology Offerings

CCL17 AS CENTRAL IMMUNE REGULATOR – CCL17 INHIBITORS FOR USE IN T HELPER CELL-DRIVEN DISEASES

The current invention is based on the identification of the role of CCL17 in the genesis of T helper cell Th1-driven diseases, in particular atherosclerosis and autoimmune diseases.

The invention provides novel therapeutic approaches for treating atherosclerosis and other diseases such as myocardial infarction, stroke, peripheral vascular disease, chronic kidney disease and angina pectoris. These approaches are based on interfering with the interaction between the CCL17-cytokine and the CCL17-receptor. Respective agents will also be beneficial for the treatment of autoimmune diseases e.g. hypersensitivity dermatitis (CHS), psoriasis, rheumatoid arthritis, Bechterew's disease and inflammatory bowel disease (Crohn`s disease).

Further Information: PDF

PROvendis GmbH
Phone: +49 (0)208/94105 10

Contact
Dipl.-Ing. Alfred Schillert

Comments (0)

Write a comment